NCT01356680View on ClinicalTrials.gov

HD17 for Intermediate Stage Hodgkin Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

January 13, 2012

Primary Completion Date

March 21, 2020

Study Completion Date

March 23, 2020

Conditions
Hodgkin Lymphoma
Interventions
DRUG

BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)

DRUG

ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)

RADIATION

30Gy IF-RT (Involved-Field Radiotherapy)

RADIATION

30Gy IN-RT (Involved-Node Radiotherapy)

Trial Locations (1)

Unknown

1st Dept. of Medicine, Cologne University Hospital, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT01356680 - HD17 for Intermediate Stage Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter